Alimta and Obstruction - a phase IV clinical study of FDA data

Summary:

Obstruction is reported as a side effect among people who take Alimta (pemetrexed disodium), especially for people who are male, 40-49 old, have been taking the drug for < 1 month also take Cisplatin, and have Non-small cell lung cancer stage iv.

The phase IV clinical study analyzes which people have Obstruction when taking Alimta. It is created by eHealthMe based on reports of 7,644 people who have side effects when taking Alimta from the FDA, and is updated regularly.

What is Alimta?

Alimta has active ingredients of pemetrexed disodium. eHealthMe is studying from 7,702 Alimta users. Check the latest studies of Alimta.

What is Obstruction?

Obstruction is found to be associated with 468 drugs and 648 conditions by eHealthMe. Check the latest studies of Obstruction.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 04, 2026

7,644 people reported to have side effects when taking Alimta.
Among them, 11 people (0.14%) have Obstruction.

Among these 11 people:

How long have people been on Alimta when they have Obstruction? *

What is the gender of people who have Obstruction when taking Alimta? *

female: 20 %
male: 80 %

What is the age of people who have Obstruction when taking Alimta? *

What are other drugs people take besides Alimta? *

What are other side effects people have besides Obstruction? *

Cytokine Release Syndrome (immediate complication occurring with the use of anti-t cell antibody infusions): 6 people, 54.55%
Tumor Pain: 4 people, 36.36%
Anaemia (lack of blood): 3 people, 27.27%
Chest Pain: 2 people, 18.18%
Disease Progression: 2 people, 18.18%
White Blood Cell Count Decreased: 1 person, 9.09%
Impaired Healing: 1 person, 9.09%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 1 person, 9.09%
Aseptic Necrosis (the death of bone tissue due to a lack of blood supply): 1 person, 9.09%
Axillary Pain: 1 person, 9.09%

What are the existing conditions these people have? *

Non-Small Cell Lung Cancer Stage Iv: 7 people, 63.64%
Chest Pain: 3 people, 27.27%
Analgesia: 2 people, 18.18%
Pleural Mesothelioma Malignant (cancer of the pleura, or the membrane that lines the lungs): 1 person, 9.09%
Metastases To Bone (cancer spreads to bone): 1 person, 9.09%
Lung Cancer Metastatic (lung cancer spreads to other parts): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Alimta and have Obstruction?

- Check whether Obstruction is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Alimta:

Alimta (7,702 reports)

Obstruction treatments and more:

Obstruction (4,654 reports)

Browse all side effects of Alimta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Obstruction:

Obstruction (468 drugs)

Browse all the conditions that are associated with Obstruction:

Obstruction (648 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on pemetrexed disodium (the active ingredients of Alimta) and Alimta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.